3.3 Collaborative Drug Therapy Management (CDTM) & Institutional Protocols

Collaborative Drug Therapy Management

Mississippi Article XXXVI permits a pharmacist to perform specified drug-therapy-management functions under a written guideline or protocol with a licensed prescribing practitioner. The protocol delegates bounded functions; it does not turn the pharmacist into an independent physician or create authority outside the practitioner’s own scope.

Who may participate

The regulation uses a licensed prescribing practitioner, not only an MD or DO. The practitioner must have authority to prescribe the drug and treat the condition at issue. The pharmacist must hold an unrestricted Mississippi pharmacist license and notify the Board through the Board’s licensing system before engaging in the authorized protocol practice. A technician cannot become a protocol provider, and the pharmacist cannot delegate professional CDTM judgment to a technician.

Written protocol

The agreement must be in writing and should identify the parties and practice setting; the disease states, patient population, and conditions covered; the drug or drug categories involved; the pharmacist functions being delegated; selection criteria and limitations; procedures and decision rules; documentation and communication; quality-assurance review; and methods for amendment or termination. The practitioner retains responsibility within the collaborative arrangement, and the pharmacist remains accountable for following the protocol and pharmacy law.

Do not add secondary-source requirements that are not in the current rule. Article XXXVI does not supply a universal annual re-signing deadline, a universal patient-consent form, or a fixed 24- or 48-hour notification interval for every intervention. The protocol itself must define operational communication and review. Other laws, institutional policies, payer terms, or professional standards may require consent or quicker communication in a particular setting, but those should not be mislabeled as the Board’s universal CDTM number.

A protocol may be effective for no more than two years. The parties should review it sooner when law, personnel, evidence, formulary, or workflow changes. Once expired or terminated, it no longer supplies delegated authority.

Scope and the controlled-substance boundary

The most important Mississippi limit is explicit: Article XXXVI protocol authority is limited to non-scheduled drugs. A pharmacist acting under this article may not initiate, modify, or discontinue a Schedule II–V controlled substance on the theory that the general protocol authorizes drug management. A separate lawful authority would be needed for any controlled-substance act.

Within a valid non-scheduled protocol, authorized functions can include collecting patient information, ordering or evaluating laboratory tests, initiating or adjusting a listed drug, monitoring response, managing adverse effects, and discontinuing therapy—only to the extent the written protocol says so. The pharmacist may not diagnose a new condition outside the arrangement, treat a person outside eligibility criteria, use an unlisted drug, ignore a referral threshold, or continue after expiration.

Documentation and communication

Each action should be entered in the patient record with the assessment, data considered, action, rationale, follow-up, and required notice to the practitioner. The active protocol must be retrievable for inspection and for staff who rely on it. Communication follows the method and timing stated in the protocol, with urgent clinical findings escalated immediately under sound patient-care standards.

Quality assurance should test whether eligible patients were managed within scope, laboratory monitoring and referrals occurred, outcomes and adverse events were reviewed, and protocol deviations were corrected. A quality program is not permission to retroactively approve an unauthorized action.

Scenario method

For any CDTM question, verify: current unrestricted pharmacist + authorized prescribing practitioner + Board notification + written protocol + unexpired term + eligible patient and condition + listed non-scheduled drug + authorized act + documentation and communication. If the drug is scheduled, stop: Article XXXVI itself does not authorize the act. If the question gives an appealing clinical intervention but omits protocol authority, clinical appropriateness alone is insufficient.

Protocol audit example

A pharmacist plans to titrate metformin, order an A1c, and adjust clonazepam for a patient enrolled in a diabetes protocol. Confirm that the protocol lists the diabetes population, metformin or its category, laboratory authority, thresholds, follow-up, and practitioner communication. The metformin and A1c actions can proceed if every condition is met. Clonazepam cannot: it is scheduled, so Article XXXVI does not supply authority regardless of protocol wording.

Now assume the protocol was signed 25 months ago. Even a clinically perfect metformin change would lack current delegated authority because the two-year maximum expired. Stop protocol acts, notify the practitioner, and renew or replace the agreement through the current process before resuming. This illustrates why drug, action, patient eligibility, and protocol date are separate gates.